Craig Cook appointed Chief Business Officer and Co-founder at ABILITY Neurotech, the Wyss Geneva's flagship spin-off
Thrilled to share that Craig Cook has been named Chief Business Officer of Ability Neurotech SA, our flagship spin-off. A key force behind our venture-building model, Craig will now help Ability Neurotech shape the future of brain-computer interfaces.
During his tenure at the Wyss Center, Craig Cook played a transformative role in establishing a strong business development framework and positioning the organization as a venture builder in neurotechnology. Under his leadership, six breakthrough technologies were successfully spun out into operational startup companies: Clee Medical SA, Brainscape Medical SA, Dataflight Ltd, BrainQuant SA, Aleos Bio SA, and ABILITY Neurotech SA.
In parallel, Craig led the onboarding of aligned startups such as Dandelion Science Corp. and dEEGtal Insights SA, strengthening our AI and neurotech ecosystem. He also contributed to Series A investments in two Wyss-affiliated companies, Artiria Medical SA and Neurosoft Bioelectronics SA, bolstering our commitment to early-stage innovation.
Now joining ABILITY Neurotech SA as Chief Business Officer and Co-founder, Craig will drive the company's fundraising strategy and operational growth. As the Wyss Center's flagship spin-off, ABILITY Neurotech is uniquely positioned to play an important role at the forefront of the brain-computer interface (BCI) revolution, ABILITY Neurotech offers a comprehensive end-to-end solution that spans neural signal capture, processing and seamless integration into clinical practice.
'Craig has been a catalyst for our mission,' said Prof. Erwin Böttinger, Director of the Wyss Center. 'His vision and energy have not only shaped our ecosystem but also brought our technologies closer to the market and to patients who need them. I look forward to seeing the continued impact of his work at ABILITY Neurotech.'
Dr. Tracy Laabs, Head of Innovation and Strategic Partnerships at the Wyss Center, added:
'Craig's transition to lead one of our spin-offs is a clear example of the success of our model. It demonstrates how our translational approach—building and spinning out high-potential startups—can bring cutting-edge neurotechnologies closer to the clinic while empowering talented individuals to lead the next wave of innovation.'
The Wyss Center extends its sincere gratitude to Craig Cook for his leadership and dedication and looks forward to continued collaboration with him in this exciting next chapter.
About Wyss Geneva: Wyss Geneva is a non-profit advancing neurotechnologies to improve lives affected by neurological and mental health disorders. Based at Campus Biotech in Geneva, it develops AI, bioengineering, and neuroengineering solutions to restore neural function and enable precision therapies. Founded in 2014 with the support of philanthropist Hansjörg Wyss, it collaborates globally to drive innovation and clinical impact
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
New Edinburgh dog park set to open with host of activities in place for pooches
A new dog park is set to open on the outskirts of Edinburgh. Situated close to the Highland Show ground just off the A8 at Gogarburn, the space is billed as the perfect area for dog owners and professional walkers to have fun with their pooches. The site has been launched by Unleash The Dogs and will open on Saturday July 5 but bookings are already open. READ MORE: Devastated Edinburgh owners shut restaurant due to 'ridiculous' experience READ MORE: Eager Edinburgh city centre shoppers in huge queues for fancy new jewellery shop Another site in Edinburgh has also been earmarked for development with the company stating a space by Fort Kinnaird will also open later this summer. Several sites have already been launched in Glasgow by Craig and his partner Lauren, who both hail from a farming background. Join Edinburgh Live's Whatsapp Community here and get the latest news sent straight to your messages. The new Edinburgh site will contain a variety of obstacle equipment for dogs of all shapes and sizes to enjoy in a secure enclosed environment. Craig, 34, said: 'This is a huge step for us. Edinburgh has a completely different layout to Glasgow, so we've worked hard to find a spot that balances that rural escapism our parks are known for, while staying easily accessible. 'The West Edinburgh field is only about a 15-minute drive from the city centre, yet it is a proper rural escape. 'We wanted to create something truly special here, not just another enclosed space but a destination for dogs and their owners.' Owners and professional dog-walkers can book their slot for up to eight dogs at a time online, guaranteeing complete private access to the site. The sites also benefit from regular staffing to ensure the grounds are immaculately maintained, ensuring a safe and clean experience for all visitors. Craig added: 'Our parks are run like five-star resorts. We have regular staff visits, bespoke features, and we never cut corners. 'It's about keeping standards sky high and creating places that owners are proud to bring their dogs to. 'We've developed a strong model in Glasgow, and the response there has been phenomenal. Edinburgh deserves the same standard – and we're here to deliver it.' Sign up for Edinburgh Live newsletters for more headlines straight to your inbox With its premium finish and proximity to the city, the new park is set to become a favourite for dog lovers across the capital. For more information about Unleash the Dogs, and how to book, click here.
Yahoo
2 days ago
- Yahoo
Craig-Hallum Initiates Coverage of Butterfly (BFLY) With a Buy Rating
Butterfly Network, Inc. (NYSE:BFLY) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Craig-Hallum analyst Chase Knickerbocker has initiated coverage of Butterfly Network, Inc. (NYSE:BFLY) with a Buy rating and a $3 price target, citing the company's disruptive position in the point-of-care ultrasound market. Butterfly's proprietary technology replaces traditional piezoelectric crystal-based ultrasound components with a chip-based semiconductor platform, allowing for a single probe to handle multiple imaging needs. This innovation not only reduces manufacturing complexity and cost, but also enables rapid software-driven improvements that set Butterfly apart from most handheld competitors. A doctor looking at a ultrasound system with a Compass software interface, demonstrating the sophistication of the device. The firm's outlook is underpinned by Butterfly's expanding direct-to-consumer (DTC) reach and a growing number of institutional partnerships, including leading health systems and academic centers. These relationships are expected to drive consistent hardware sales while building recurring revenue from software subscriptions. Butterfly Network's technology also places it at the forefront of healthcare's digital transformation. By combining advanced imaging with real-time data interpretation and cloud-based collaboration tools, the company is integrating AI into clinical workflows to enhance diagnostic speed and accuracy. While we acknowledge the potential of BFLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BFLY and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio
Business Wire
4 days ago
- Business Wire
Pediatrix Board Appoints Kurt D. Newman, M.D. as Independent Director
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today announced that its board of directors has appointed Kurt D. Newman, M.D., former President and Chief Executive Officer of Children's National Hospital in Washington, D.C. and Professor Emeritus of Surgery and Pediatrics at George Washington University School of Medicine and Health Sciences, as an independent director, effective July 1, 2025. Dr. Newman, a surgeon and nationally recognized leader in pediatric healthcare and a long-term healthcare executive, served as President and Chief Executive Officer of Children's National Hospital for 12 years, after spending over 25 years there as a pediatric surgeon. Dr. Newman fostered a culture of patient-centered care and championed a culture of innovation in research, operations and clinical care. Dr. Newman is a strong advocate for expanding mental health access for children and has led two national forums on this issue. He is the author of a best-selling book, 'Healing Children: a Surgeon's Stories from the Frontiers of Pediatric Medicine.' Dr. Newman was recognized as 'CEO of the Year' by the Washington Business Journal in 2021 and inducted into the Washington Business Hall of Fame in 2023. 'On behalf of the Pediatrix board, I am honored to welcome Dr. Newman,' said Guy Sansone, Pediatrix Lead Independent Director. 'Dr. Newman's clinical insight, patient-centric perspective, and profound understanding of the healthcare landscape will be invaluable as we navigate the challenges and opportunities ahead. We look forward to Dr. Newman's contributions as we work together to advance our mission.' 'We are thrilled to welcome Dr. Newman. His deep understanding of patient needs, clinical practices and the evolving healthcare landscape will be a tremendous asset to Pediatrix leadership,' said Mark S. Ordan, Chair of the Board of Directors and Chief Executive Officer. 'It is a great honor to join the board of Pediatrix, an organization that plays a significant role in caring for the most vulnerable patients and a vital role in advancing clinical excellence,' said Dr. Kurt Newman. 'The physician voice is central to patient-centered decision making. I look forward to contributing my experience to strengthen collaboration between physicians, other clinicians, executive leadership and the board so that patient care remains at the forefront, with the goal of building a more sustainable, resilient and effective healthcare system for all." Dr. Newman serves on the boards of Children's Miracle Network Hospitals, Corus International, Fight for Children and the Potomac Conservancy and previously served on the boards of Children's National Hospital and YMCA Camp Sea Gull/Seafarer. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group's high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,400 affiliated physicians and other clinicians. To learn more about Pediatrix, visit or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company's objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as 'believe,' 'hope,' 'may,' 'anticipate,' 'should,' 'intend,' 'plan,' 'will,' 'expect,' 'estimate,' 'project,' 'positioned,' 'strategy' and similar expressions, and are based on assumptions and assessments made by the Company's management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company's most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled 'Risk Factors', as well the Company's current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the impact of the Company's practice portfolio management plans and whether the Company is able to achieve the expected favorable impact to Adjusted EBITDA therefrom; the impact of the Company's termination of its then third-party revenue cycle management provider and transition to a hybrid revenue cycle management model with one or more new third-party service providers, including any transition costs associated therewith; the impact of surprise billing legislation; the effects of economic conditions on the Company's business; the effects of the Affordable Care Act and potential healthcare reform; the Company's relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the Company's ability to comply with the terms of its debt financing arrangements; the impact of management transitions; the timing and contribution of future acquisitions or organic growth initiatives; the effects of share repurchases; and the effects of the Company's transformation initiatives, including its reorientation on, and growth strategy for, its hospital based and maternal fetal businesses.
